Quest Diagnostics PE Ratio 2010-2025 | DGX
Current and historical p/e ratio for Quest Diagnostics (DGX) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Quest Diagnostics PE ratio as of July 10, 2025 is 18.86.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Quest Diagnostics PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2025-07-10 |
171.45 |
|
21.68 |
| 2025-03-31 |
167.61 |
$7.91 |
21.19 |
| 2024-12-31 |
148.72 |
$7.69 |
19.34 |
| 2024-09-30 |
152.29 |
$7.44 |
20.47 |
| 2024-06-30 |
133.56 |
$7.41 |
18.02 |
| 2024-03-31 |
129.14 |
$7.43 |
17.38 |
| 2023-12-31 |
133.06 |
$7.49 |
17.77 |
| 2023-09-30 |
116.92 |
$6.66 |
17.56 |
| 2023-06-30 |
134.17 |
$6.87 |
19.53 |
| 2023-03-31 |
134.38 |
$6.78 |
19.82 |
| 2022-12-31 |
147.93 |
$7.92 |
18.68 |
| 2022-09-30 |
115.39 |
$10.17 |
11.35 |
| 2022-06-30 |
124.47 |
$12.02 |
10.35 |
| 2022-03-31 |
126.86 |
$15.02 |
8.45 |
| 2021-12-31 |
159.67 |
$15.56 |
10.26 |
| 2021-09-30 |
133.53 |
$16.65 |
8.02 |
| 2021-06-30 |
120.70 |
$16.77 |
7.20 |
| 2021-03-31 |
116.83 |
$13.17 |
8.87 |
| 2020-12-31 |
107.99 |
$10.44 |
10.34 |
| 2020-09-30 |
103.24 |
$8.09 |
12.76 |
| 2020-06-30 |
102.27 |
$5.51 |
18.56 |
| 2020-03-31 |
71.52 |
$5.81 |
12.31 |
| 2019-12-31 |
94.64 |
$6.28 |
15.07 |
| 2019-09-30 |
94.37 |
$5.34 |
17.67 |
| 2019-06-30 |
89.31 |
$5.31 |
16.82 |
| 2019-03-31 |
78.42 |
$5.22 |
15.02 |
| 2018-12-31 |
72.17 |
$5.29 |
13.64 |
| 2018-09-30 |
93.08 |
$6.19 |
15.04 |
| 2018-06-30 |
94.41 |
$5.81 |
16.25 |
| 2018-03-31 |
85.69 |
$5.61 |
15.27 |
| 2017-12-31 |
83.76 |
$5.50 |
15.23 |
| 2017-09-30 |
79.26 |
$4.77 |
16.62 |
| 2017-06-30 |
93.70 |
$4.96 |
18.89 |
| 2017-03-31 |
82.39 |
$4.96 |
16.61 |
| 2016-12-31 |
76.74 |
$4.50 |
17.05 |
| 2016-09-30 |
70.67 |
$4.70 |
15.04 |
| 2016-06-30 |
67.32 |
$5.71 |
11.79 |
| 2016-03-31 |
58.76 |
$5.15 |
11.41 |
| 2015-12-31 |
58.18 |
$4.87 |
11.95 |
| 2015-09-30 |
49.96 |
$4.87 |
10.26 |
| 2015-06-30 |
58.63 |
$3.40 |
17.24 |
| 2015-03-31 |
61.82 |
$3.51 |
17.61 |
| 2014-12-31 |
53.69 |
$3.80 |
14.13 |
| 2014-09-30 |
48.31 |
$3.48 |
13.88 |
| 2014-06-30 |
46.47 |
$5.28 |
8.80 |
| 2014-03-31 |
45.61 |
$5.43 |
8.40 |
| 2013-12-31 |
41.92 |
$5.57 |
7.53 |
| 2013-09-30 |
48.38 |
$4.94 |
9.79 |
| 2013-06-30 |
47.25 |
$3.27 |
14.45 |
| 2013-03-31 |
43.78 |
$3.31 |
13.23 |
| 2012-12-31 |
44.71 |
$3.45 |
12.96 |
| 2012-09-30 |
48.67 |
$4.30 |
11.32 |
| 2012-06-30 |
45.84 |
$4.36 |
10.51 |
| 2012-03-31 |
46.66 |
$4.27 |
10.93 |
| 2011-12-31 |
44.05 |
$4.14 |
10.64 |
| 2011-09-30 |
37.37 |
$3.91 |
9.56 |
| 2011-06-30 |
44.74 |
$3.97 |
11.27 |
| 2011-03-31 |
43.55 |
$4.02 |
10.83 |
| 2010-12-31 |
40.65 |
$4.05 |
10.04 |
| 2010-09-30 |
38.01 |
$4.06 |
9.36 |
| 2010-06-30 |
37.33 |
$3.95 |
9.45 |
| 2010-03-31 |
43.65 |
$3.89 |
11.22 |
| 2009-12-31 |
45.14 |
$3.88 |
11.63 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$19.140B |
$9.872B |
|
Quest Diagnostics, Inc. is the provider of commercial laboratory services. Quest provides lab testing services to physicians, hospitals, managed care organizations, employers, government institutions and other clinical laboratories. The company consists of 2 business groups - Diagnostic Information Services and Diagnostic Solutions. The company's focus is on two elements - to accelerate growth and to drive operational excellence. Restore Growth: The company has adopted seven tactical approaches to accelerate growth such as sales and marketing; development of esoteric testing through a disease focus; partnerships with hospitals and successful testing of international IDNs; creation of value from information assets; leadership in companion diagnostics; extension into adjacent markets. Drive Operational excellence: The company plans to focus on four strategic requirements - to enhance end-to-end customer value chain, enterprise information technology architecture, business performance tools and cost excellence.
|
